亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

恩扎鲁胺 医学 中止 前列腺癌 耐受性 内科学 队列 雄激素受体 肿瘤科 不利影响 癌症
作者
Daniel J. George,Alicia K. Morgans,Niculae Constantinovici,Nasreen Khan,Javeed Khan,Guifang Chen,Vlasta Hlebec,Neal D. Shore
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (8): e2429783-e2429783
标识
DOI:10.1001/jamanetworkopen.2024.29783
摘要

Importance Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use and tolerability. Objective To compare clinical use and outcomes for darolutamide, enzalutamide, and apalutamide in patients with nmCRPC. Design, Setting, and Participants This retrospective cohort study reviewed electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC and no prior novel hormonal therapy and initiated novel ARI treatment between August 1, 2019, and March 31, 2022. Data were analyzed from February 1, 2019, to December 31, 2022. Exposures Patients were prescribed darolutamide, enzalutamide, or apalutamide as their first novel ARI for nmCRPC. Main Outcomes and Measures The main outcome was a composite of 2 end points, treatment discontinuation and progression to metastatic CRPC (mCRPC), whichever occurred first. Both end points were also assessed separately. Results All 870 patients meeting eligibility criteria were included (362 receiving darolutamide [41.6%]; 382, enzalutamide [43.9%]; 126, apalutamide [14.5%]); mean (SD) age was 78.8 (8.7) years. Self-reported race was Black or African American in 187 patients (21.5%), White in 585 (67.2%), and other or unknown in 98 (11.3%). The darolutamide cohort had lower proportions of patients with a composite end point event (134 [37.0%] vs 201 [52.6%] for enzalutamide and 66 [52.4%] for apalutamide), discontinuation (110 [30.4%] for darolutamide vs 156 [40.8%] for enzalutamide and 58 [46.0%] for apalutamide), and progression to mCRPC (64 [17.7%] for darolutamide vs 108 [28.3%] for enzalutamide and 35 [27.8%] for apalutamide) during the study period. After adjusting for baseline covariates, patients receiving darolutamide had a lower risk of a composite end point event compared with enzalutamide (risk reduction, 33.8%; hazard ratio [HR], 0.66 [95% CI, 0.53-0.84]) and apalutamide (risk reduction, 35.1%; HR, 0.65 [95% CI, 0.48-0.88]). Similarly, patients receiving darolutamide had a lower risk of discontinuation compared with enzalutamide (risk reduction, 27.4%; HR, 0.73 [95% CI, 0.56-0.94]) and apalutamide (risk reduction, 39.1%; HR, 0.61 [95% CI, 0.44-0.85]) and a lower risk of progression to mCRPC compared with enzalutamide (risk reduction, 40.6%; HR, 0.59 [95% CI, 0.43-0.82]) and apalutamide (risk reduction, 35.3%; HR, 0.65 [95% CI, 0.42-0.99]). There was no difference between enzalutamide and apalutamide treatment across outcomes. Conclusions and Relevance In this large cohort study of patients with nmCRPC treated with novel ARIs, results suggest better tolerability for darolutamide compared with enzalutamide and apalutamide, which may be associated with a clinical effectiveness advantage. Comparative clinical studies are needed to guide treatment decisions in the absence of head-to-head clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏应助Dc采纳,获得10
25秒前
1分钟前
情怀应助科研通管家采纳,获得10
1分钟前
2分钟前
Dc发布了新的文献求助10
2分钟前
Dc完成签到,获得积分10
2分钟前
2分钟前
幽默平安发布了新的文献求助10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
4分钟前
4分钟前
4分钟前
小禾一定行完成签到 ,获得积分10
4分钟前
inkoin发布了新的文献求助10
4分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
inkoin完成签到,获得积分10
5分钟前
5分钟前
积极的台灯应助Akitten采纳,获得10
6分钟前
隐形曼青应助务实书包采纳,获得10
6分钟前
6分钟前
6分钟前
爱思考的小笨笨完成签到,获得积分10
7分钟前
GingerF应助科研通管家采纳,获得50
7分钟前
GingerF应助科研通管家采纳,获得50
7分钟前
上官若男应助闫雪采纳,获得10
7分钟前
7分钟前
7分钟前
Akitten发布了新的文献求助10
8分钟前
8分钟前
大写的LV完成签到 ,获得积分10
8分钟前
ffff完成签到 ,获得积分10
8分钟前
zsmj23完成签到 ,获得积分0
9分钟前
Owen应助科研通管家采纳,获得10
9分钟前
Owen应助hongtao采纳,获得10
9分钟前
9分钟前
哈哈哈完成签到 ,获得积分10
9分钟前
10分钟前
liu完成签到 ,获得积分10
11分钟前
33发布了新的文献求助10
11分钟前
11分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990219
求助须知:如何正确求助?哪些是违规求助? 3532146
关于积分的说明 11256472
捐赠科研通 3271042
什么是DOI,文献DOI怎么找? 1805190
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234